Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cassava Sciences (SAVA)
NASDAQ:SAVA
Cassava Sciences (SAVA) Stock Price & Analysis
3,063 Followers
SAVA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.79 - $32.10
Previous Close$10.22
Volume2.70M
Average Volume (3M)1.36M
Market Cap
$490.08M
Enterprise Value$368.94M
Total Cash (Recent Filing)$121.14M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.27
Next Earnings
Jul 31, 2024EPS Estimate
-$0.41Last Dividend Ex-Date
Dec 13, 2012Dividend YieldN/A
Share Statistics
EPS (TTM)-2.16
Shares Outstanding47,976,166
10 Day Avg. Volume656,650
30 Day Avg. Volume1,364,446
Standard Deviation0.61
R-Squared0.00178
Alpha0.16
Financial Highlights & Ratios
Price to Book (P/B)5.37
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-12.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.94
Forecast
1Y Price Target
$107.00Price Target Upside947.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Cassava Sciences News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe ongoing Phase 3 trials are powered adequately to show statistically significant results if data were to be stratified by mild and moderate Alzheimer's disease patients.
Market PotentialThere is a clear market for an effective oral drug with a clean safety profile, especially with the low sales uptake of Leqembi in the recent quarter.
Safety ProfileThe safety profile is a major advantage as there were no drug-related serious adverse events after 24 months of treatment.
Bears Say
InvestigationsDOJ and SEC investigations into the Company and two senior employees.
Legal IssuesFederal grand jury indictment of the former consultant of Cassava Sciences.
Valuation UncertaintyMultiple sources of uncertainties to be able to meaningfully value the stock.
---
Ownership Overview
34.10% Insiders
7.25% Mutual Funds
13.43% Other Institutional Investors
45.23% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SAVA FAQ
What was Cassava Sciences’s price range in the past 12 months?
Cassava Sciences lowest stock price was $8.79 and its highest was $32.10 in the past 12 months.
What is Cassava Sciences’s market cap?
Currently, no data Available
When is Cassava Sciences’s upcoming earnings report date?
Cassava Sciences’s upcoming earnings report date is Jul 31, 2024 which is in 24 days.
How were Cassava Sciences’s earnings last quarter?
Cassava Sciences released its earnings results on May 10, 2024. The company reported -$0.43 earnings per share for the quarter, beating the consensus estimate of -$0.46 by $0.03.
Is Cassava Sciences overvalued?
According to Wall Street analysts Cassava Sciences’s price is currently Undervalued.
Does Cassava Sciences pay dividends?
Cassava Sciences pays a Notavailable dividend of $5.25 which represents an annual dividend yield of N/A. See more information on Cassava Sciences dividends here
What is Cassava Sciences’s EPS estimate?
Cassava Sciences’s EPS estimate is -$0.41.
How many shares outstanding does Cassava Sciences have?
Cassava Sciences has 47,976,166 shares outstanding.
What happened to Cassava Sciences’s price movement after its last earnings report?
Cassava Sciences reported an EPS of -$0.43 in its last earnings report, beating expectations of -$0.46. Following the earnings report the stock price went up 1.928%.
Which hedge fund is a major shareholder of Cassava Sciences?
Among the largest hedge funds holding Cassava Sciences’s share is Gallacher Capital Management LLC. It holds Cassava Sciences’s shares valued at 12M.
---
Cassava Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$107.00 (947.48% Upside)
$107.00 (947.48% Upside)
Blogger Sentiment
Bullish
SAVA Sentiment 79%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 5.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.65%
12-Months-Change
Fundamentals
Return on Equity
-33.90%
Trailing 12-Months
Asset Growth
-28.61%
Trailing 12-Months
Company Description
Cassava Sciences
Cassava Sciences, Inc. engages in the development of novel drugs. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.
---
SAVA Stock 12 Month Forecast
Average Price Target
$107.00
▲(947.48% Upside)
Technical Analysis
Best Analysts Covering SAVA
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-54.15%
reiterated a buy rating 25 days ago
Copying Elemer Piros's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -54.15% per trade.
---